Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Scandinavian ChemoTech AB (publ)
  6. News
  7. Summary
    CMOTEC B   SE0009242654

SCANDINAVIAN CHEMOTECH AB (PUBL)

(CMOTEC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Scandinavian ChemoTech : strengthens its working capital through loans of SEK 10 million

04/30/2021 | 06:02am EDT

The Company has today entered into an agreement to strengthen its working capital by raising a loan from two privately owned companies of a maximum of SEK 10 million. A loan that creates the conditions for the increased market activity and to continue to drive clinical development.

The agreement signed today strengthens the Company's finances after previous loans from Erik Penser Bank and an external financier of SEK 5.5 million were repaid during the first quarter of the year. This new credit, which extends to the end of 2021, will lift the Company's financial position and contribute to the expansive development that the Company plans to undergo.

The loan is raised on market terms.

"It feels good to find such a flexible solution that creates an expanded space for the Company's development. In the current times it feels safe to have a financial buffer, which this agreement now provides us with. " says Mohan Frick, CEO

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel:  Corporate Finance AB, Tel: +46 8-463 80 00, 

E-mail: certifiedadviser@penser.se

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU's market abuse regulation. The information was submitted by the agency of above stated contact person, to be made public on Friday 30th of April 2021 at 11.15 (CET).

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.

https://news.cision.com/chemotech/r/scandinavian-chemotech-strengthens-its-working-capital-through-loans-of-sek-10-million,c3337778

https://mb.cision.com/Main/14967/3337778/1410773.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about SCANDINAVIAN CHEMOTECH AB (PUBL)
07/16SCANDINAVIAN CHEMOTECH : Board member buys additional shares in Scandinavian Che..
AQ
07/08SCANDINAVIAN CHEMOTECH : starts a feasibility study ináthe USA
AQ
07/08Scandinavian ChemoTech Starts Feasibility Study in the USA
CI
06/17SCANDINAVIAN CHEMOTECH : receives approval from the European Patent Office
AQ
06/17Scandinavian ChemoTech Receives Approval from the European Patent Office
CI
06/08SCANDINAVIAN CHEMOTECH : Board member buys additional shares in Scandinavian Che..
AQ
06/03SCANDINAVIAN CHEMOTECH : Board members buys additional shares in Scandinavian Ch..
AQ
05/31SCANDINAVIAN CHEMOTECH AB : is gearing up after a successful CE marking
AQ
05/26SCANDINAVIAN CHEMOTECH AB : has received approval for the CE marking
AQ
05/26Scandinavian Chemotech AB Receives Approval for the CE Marking
CI
More news
Financials
Sales 2021 - - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 251 M 29,1 M 29,2 M
Capi. / Sales 2021 -
Capi. / Sales 2022 53,4x
Nbr of Employees 7
Free-Float 56,5%
Chart SCANDINAVIAN CHEMOTECH AB (PUBL)
Duration : Period :
Scandinavian ChemoTech AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Last Close Price 29,05 SEK
Average target price 21,50 SEK
Spread / Average Target -26,0%
Managers and Directors
Stefan Mohan Frick Chief Executive Officer & Director
Lars Olof Hedbys Chairman
Urban Hňkan WidÚn Chief Operating Officer
Bengt Georg Gustaf Engstr÷m Director
Rolf Bertil Ehrnstr÷m Director
Sector and Competitors